Stevanato: Strategies for Optimising the Pharma Supply Chain

The pharmaceutical industry witnessing an unprecedented surge in demand for GLP-1 medications, driven by rising rates of diabetes and obesity worldwide.

As these groundbreaking treatments gain traction for their dual benefits in managing blood sugar levels and promoting significant weight loss, manufacturers face the critical challenge of building supply chains capable of meeting global demand whilst maintaining quality and efficiency.

Raffaele Pace, President of Engineering Business Unit at Stevanato Group, is well placed to offer valuable insights into the strategies pharmaceutical companies must adopt to optimise their GLP-1 supply chains and ensure life-changing medications reach patients who need them.

The scale of the challenge

The market potential for GLP-1 medications is staggering, with projections reaching US$100bn by by 2030, according to J.P. Morgan. The pharmaceutical industry must rapidly evolve its manufacturing and distribution capabilities to meet this explosive growth.

"The rapid growth in demand for GLP-1s has underscored a critical need for resilient and adaptable supply chains," explains Raffaele.

"While initial supply constraints have eased, vulnerabilities of existing systems have been revealed, similarly to those seen during the early days of COVID vaccine production."

Drawing lessons from the pandemic response, Raffaele notes that the COVID-19 pandemic response "demonstrated the value of an agile production infrastructure, capable of scaling quickly and efficiently in response to global needs".

He emphasises that, as GLP-1 usage expands worldwide, ensuring a flexible and robust manufacturing and distribution network will be essential to meet ongoing demand and ensure supply chain resilience.

Harnessing automation and digitalisation

Advanced technologies are fundamentally transforming how pharmaceutical companies approach GLP-1 manufacturing.

"In the pharmaceutical industry, control over replicable processes is essential, and automation ensures that the required volumes are produced within given timeframes," says Raffaele.

"Employing solutions supported by AI and digitalisation in visual inspection and device assembly enable flexibility for pharma manufacturers, support faster time-to-market and enhanced control over processes."

The integration of AI into manufacturing processes offers particular promise.

Raffaele describes a compelling vision: "Imagine a state-of-the-art production line for GLP-1 drugs where high-speed visual inspection equipment is integrated with AI algorithms.

"With advanced analytical tools for identifying and classifying defective products with greater accuracy and robustness, AI can increase the defect detection rate while reducing false rejects. This enables significant cost savings and streamlines production, allowing manufacturers to optimise throughput and accelerate time-to-market."

Raffaele adds: "By incorporating such advanced technologies, pharmaceutical companies can ensure that their GLP-1 production lines are not only more efficient but also more reliable, ultimately improving product quality and consistency while reducing waste."

The promise of digital twins

Beyond AI-powered inspection systems, digital twins represent another frontier in pharmaceutical manufacturing optimisation.

"Digital twins can play a central role in digitalisation to optimise performance," Raffaele continues. "For instance, in assembly line production, a company can create a virtual replica of the entire assembly process before physically building the equipment.

"This allows manufacturers to test, validate and optimise the production line's performance virtually, identifying potential inefficiencies or issues before they arise in the real-world setup."

Raffaele says this application of digital twins in pharmaceutical production "could ultimately lead to faster, more reliable and more efficient assembly of critical devices," supporting a more agile and responsive supply chain.

Building flexibility into manufacturing

Continuous innovation remains essential to meet the evolving demands of the GLP-1 market. "By investing in solutions that enhance manufacturing flexibility and reliability, pharmaceutical companies can better manage demand fluctuations and maintain a steady supply of these critical medications," Raffaele notes.

He observes that market shifts are increasing the need for new devices, varied batch sizes and the capacity to sustain high-volume production for widely used treatments.

"Modern manufacturing facilities must adapt by minimising downtime and maximising flexibility," says Raffaele. "Equipment should accommodate multiple formats and enable rapid, seamless changeovers to support diverse production requirements.

"This adaptability is crucial for meeting market needs while maintaining efficiency and quality in GLP-1 medication production."

From clinical trials to global supply

Perhaps most crucially, Raffaele advocates for a fundamental shift in manufacturing strategy.

"Placing automation and modularity at the core of manufacturing strategies allows companies to scale production from clinical trials to high volumes," he asserts. "The pharma industry's ability to adapt and scale efficiently is vital for global health progress."

Looking at the broader picture, Raffaele concludes: "Optimising the GLP-1 supply chain requires a strategic focus on automation, digitalisation and flexible platforms. By prioritising these areas, manufacturers can boost efficiency, reduce bottlenecks and respond quickly to ensure patient access and improved health outcomes."

As global demand for GLP-1 medications continues to grow, the pharmaceutical companies that embrace these innovative supply chain strategies will be best positioned to meet patient needs while maintaining the quality and reliability that these critical treatments demand.